# To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

> **NCT01068860** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 246 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Impaired Glucose Tolerance

## Interventions

- **DRUG:** Canakinumab 150 mg
- **DRUG:** Placebo to Canakinumab

## Key facts

- **NCT ID:** NCT01068860
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2011-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01068860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01068860, "To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01068860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*